Nasopharyngeal carcinoma (NPC) is etiologically associated with Epstein-Barr virus (EBV) infection and is known to be highly vascularized. Previous studies have suggested that EBV oncoproteins contribute to NPC angiogenesis. However, the regulatory network of EBV in angiogenesis still remains elusive. Herein, we reveal a novel mechanism of EBV-induced angiogenesis in NPC. First, we showed that EBVinfected NPC cell lines generated larger tumors with more microvessels in mouse xenograft models. Subsequent proteomic analysis revealed that EBV infection increased the expression of a series of angiogenic factors, including chemokine (C-C motif) ligand 5 (CCL5). We then proved that CCL5 was a target of EBV in inducing tumor angiogenesis and growth. Further investigation through transcriptome analysis indicated that the pro-angiogenic function of CCL5 might be mediated by the PI3K/AKT pathway. Furthermore, we confirmed that activation of the PI3K/AKT and hypoxia-inducible factor-1a pathways was essential for CCL5-promoted angiogenesis. Finally, the immunohistochemical analysis of human NPC specimens also showed that CCL5 was correlated with angiogenesis. Taken together, our study identifies CCL5 as a key EBV-regulated molecular driver that promotes NPC angiogenesis, suggesting it as a potential therapeutic target. Therefore, exploring the molecular mechanism underlying NPC angiogenesis is essential to developing more effective antivascular agents for NPC treatment.
Epstein-Barr virus (EBV) infection has been widely studied as an etiological factor in NPC. All EBV-infected NPC cells show type II latency, with expression of EBER, LMP1, LMP2A, LMP2B, EBNA1, and BamHI A rightward transcript microRNAs. 5 These viral genes induce multiple oncogenic properties, including tumor angiogenesis. 5 O'Neil et al 6 reported that EBNA1 enhances angiogenesis in vitro by modulating the activator protein-1 pathway in NPC; Yang et al 7 reported that LMP1 promotes vasculature formation through the JNKs/HIF-1 pathway in NPC. However, the function of a single protein might not fully reflect the effects of EBV infection. The regulatory network in EBV-induced angiogenesis remains elusive.
In this study, we confirmed that EBV infection enhances tumor angiogenesis and growth. Furthermore, we found that EBV increases the production of multiple angiogenesis-related proteins and that one of these proteins, CCL5, is a novel molecular driver underlying EBV-induced angiogenesis and tumor progression in NPC.
| MATERIALS AND METHODS

| Cell culture
Human poorly differentiated NPC cell lines, CNE2 and TW03, were kindly provided by Professor Mu-Sheng Zeng from the SYSUCC (Guangzhou, China). They were cultured in RPMI-1640 media (Invitrogen, Carlsbad, CA, USA) supplemented with 5% FBS (Gibco, Carlsbad, CA, USA). The EBV-infected NPC cell lines, CNE2-EBV and TW03-EBV, were cultured in selective media containing 200-500 lg/mL G418 (Invitrogen). Before using them for cytological experiments, the selective media were replaced with normal media. Immortalized HUVECs were kindly provided by Professor Wen-Lin Huang (SYSUCC). They were cultured in DMEM (Invitrogen) supplemented with 10% FBS (Gibco). All cell lines were maintained in a 5% CO 2 humidified incubator at 37°C and were passaged less than 10 times after initial revival from frozen stocks.
| Epstein-Barr virus infection
CNE2-EBV and TW03-EBV cell lines were derived from parental cell lines that were infected with recombinant EBV according to previous reports. 8, 9 Briefly, the procedures were as follows. The EGFP-neo 0 EBV-infected Akata cells (lymphoma cells) were used to produce recombinant EBV. First, Akata cell suspension (5 9 10 6 / mL) was incubated in serum-free media and stimulated by serum IgG cross-linking for a switch of EBV infection from latency to lysis. Next, the cells were washed with PBS to remove serum IgG and were cocultured with monolayer NPC cells (CNE2 and TW03) for 3 days. The NPC cells were then washed with PBS and screened in selective media containing 200-700 lg/mL G418 for 2-3 weeks. The infection efficiency was examined with EBER in situ hybridization.
| Preparation of conditioned media
For the following series of experiments, cells were first cultured in RPMI-1640 complete media (5% FBS) in 6-well plates. After reaching confluence, the cells were washed with PBS and cultured in serum-free media (2 mL/well) for 24 hours. Cell supernatants were collected as the CM and stored at À80°C until use. For collecting CM in chemical inhibition experiments, the PI3K inhibitor LY294002 (Selleckchem, Houston, TX, USA), the HIF-1a inhibitor PX478 (Selleckchem), the CCR1 antagonist BX471 (Tocris, Bristol, UK), the CCR3 antagonist SB297006 (Tocris), or the CCR5 antagonist DAPTA (Tocris) was used to pretreat cells for 6 hours. The cells were then washed and cultured in serum-free media for collecting CM.
| Migration assay
The migration assay was carried out using Transwell chambers (24- well plate format) with an 8.0-lm pore size (Corning, Corning, NY, USA). The HUVECs (1 9 10 5 cells/well) suspended in serum-free media were seeded into the upper chamber and were incubated in the bottom chamber with CM. The cells were cultured in a 5% CO 2 humidified incubator at 37°C for 24 hours, fixed in 4% paraformaldehyde for 10 minutes, and stained with a crystal violet staining solution (Beyotime, Shanghai, China) for 20 minutes. The cells on the upper side of the filters were removed, while the stained cells on the bottom side were photographed in three independent fields of each well through a light microscope at 1009 magnification.
The cells were counted using ImageJ software. Experiments were repeated at least three times.
| Tube formation assay
Matrigel matrix (Corning) was thawed at 4°C overnight. 
| Transcriptome analysis
Total RNA was extracted from EBV-uninfected and EBV-infected cells using TRIzol reagent (Invitrogen) according to the manufacturer's protocol. The purity and concentration of total RNA were determined by spectrophotometry. RNA integrity was confirmed by agarose gel electrophoresis. The transcriptome analysis was undertaken by NovoGene (Beijing, China). Briefly, the procedures were as follows. First, mRNA was isolated from the total RNA and was fragmented into pieces by fragmentation buffer. Second, the mRNA fragments were reverse-transcribed to cDNA for constructing libraries, followed by paired-end sequencing. Finally, the raw data were filtered, resulting in more accurate data. Functional annotation and enrichment analysis were carried out with the Gene Ontology database. Pathway enrichment was undertaken with the KEGG database.
| Western blot analysis
Cells were lysed in RIPA lysis buffer containing protease inhibitors.
The proteins in lysates were separated with 10% SDS-PAGE and then were transferred to PVDF membranes (Thermo Fisher Scien- 
| Xenograft tumor model
The BALB/c nude mice (female, 3-4 weeks old) were purchased from Shanghai Laboratory Animal Center (Shanghai, China). To identify blood vessels, representative tumor tissues were stained with an anti-mouse CD31 antibody (#77699; Cell Signaling Technology). The number of microvessels stained by CD31 was assessed using the vascular hotspot method according to previous reports. [12] [13] [14] Tumor sections were scanned at low-power field ( were analyzed in three sections. In our study, the lumen size of microvessels was not calculated.
| Statistical analysis
The data were analyzed with GraphPad Prism 6.0 software and are 
| Data availability
The transcriptome has been deposited in the Sequence Read Archive database (accession no. SRP118175).
3 | RESULTS
| Epstein-Barr virus-infected NPC cell lines
generate larger tumors with more microvessels in mouse xenograft models
To determine the role of EBV infection in tumor angiogenesis, we examined whether EBV infection directly modulates endothelial cell behaviors, such as tube formation and migration, both of which are indicative of angiogenesis. 15 We established EBV-infected NPC cells as previously described. 8, 9 Two typical NPC cell lines (CNE2 and TW03) were infected with recombinant EBV, and the presence of EBV was confirmed by EBER in situ hybridization ( Figure S1 ). Using the stable EBV-infected NPC cells (CNE2-EBV and TW03-EBV), we first collected CM and applied them to HUVECs for tube formation assays. However, no increase in HUVEC tube formation was MA ET AL.
| 1713 observed compared with their parental cells ( Figure 1A,B) . Vascular endothelial cell migration is a critical step and another indicator of angiogenesis ability. 16 We 
| Chemokine CCL5 is required for EBV-induced tumor angiogenesis
To understand the molecular basis of EBV-induced tumor angiogenesis, we used proteomics to analyze the angiogenesis-related proteins in the CM from EBV-infected and -uninfected cells. We found that a total of nine pro-angiogenic factors were collectively upregulated in the CM of CNE2-EBV and TW03-EBV cells compared with their parental cells ( Figure 3A ). Among these differentially secreted pro-angiogenic factors, CCL5 attracted our interest.
Chemokine CCL5 was historically shown to be involved in several chronic inflammations and to play a direct role in inflammation angiogenesis. 17 It has been reported that CCL5 promotes VEGFdependent angiogenesis in human osteosarcoma cells. 18 In addition, CCL5 can promote angiogenic phenotypes of glioblastoma 19 and breast cancer. 20 Furthermore, CCL5 plays an important role in promoting the differentiation of ovarian cancer stem cells into endothelial cells and tumor angiogenesis. 21 These reports indicate that CCL5 is associated with tumor angiogenesis. Whether CCL5
mediates EBV-induced angiogenesis in NPC remains unknown.
Therefore, we carried out the following assays to illustrate it. We first validated the proteomics data by ELISA, qPCR, and Western blotting. The results showed that CCL5 secretion and transcription were both increased after EBV infection, which were consistent with the proteomics analysis ( Figure 3B , right panel; Figure S3A , left panel). Similar results were obtained for another two key proangiogenic factors, VEGF ( Figure 3B , left panel; Figure S3B ) and ANG ( Figure 3B , middle panel; Figure S3A , right panel). Moreover, in EBNA1 knockdown cells, the expression of CCL5 was also decreased, confirming the regulation of CCL5 by EBV ( Figure S3C ). 
| Transcriptome analysis reveals that the PI3K/ AKT pathway is activated by EBV infection
Given that CCL5 is a key regulator in EBV-induced tumor angiogenesis, we next examined the specific mechanisms underlying CCL5-regulated angiogenesis. We isolated total RNA from EBV- Figure 4A , lower panel). We then carried out a pathway enrichment analysis for the differentially expressed genes using the KEGG database. In the analysis of the downregulated genes, significant pathways were not identified (Figure S4) . However, we identified multiple signaling pathways for the upregulated genes ( Figure 4B ). Among them, only the hematopoietic cell lineage, the PI3K/AKT and tumor necrosis factor pathways were identified from both the EBV-infected cell lines ( Figure 4B ).
Because of the critical role of the PI3K/AKT pathway in tumor angiogenesis and progression, 22 we chose it for further analysis.
According to the KEGG database, a number of genes involved in activation of the PI3K/AKT pathway were upregulated in CNE2-EBV and TW03-EBV cells, and they could be divided into several clusters, such as the growth factor and the ECM ( Figure 4C ).
Upregulating the genes in the clusters can activate the corresponding upstream signaling and may ultimately induce activation of the PI3K/AKT pathway ( Figure 4D ).
| Involvement of PI3K/AKT and HIF-1a pathways in CCL5-mediated tumor angiogenesis
To confirm the transcriptome analysis, the level of AKT phosphorylation (Ser473) was investigated by Western blotting. The results
showed that the AKT phosphorylation was increased in EBV-infected cells ( Figure 5A ). Additionally, we also examined the expression of HIF-1a, which is a target of the PI3K/AKT pathway 23 and plays a central role in tumor angiogenesis. 24 The accumulation of HIF-1a
proved to be increased after EBV infection ( Figure 5A) . The Tumor volume was measured on the indicated days after cell implantation. G,H, CD31 staining was used to visualize blood vessels in tumors formed by CNE2 or CNE2-EBV cells. H&E staining was used to identify tumor cells. The color of the staining is similar to that of the annotation. Arrows indicate blood vessels. The number of vessels was analyzed statistically. Scale bar = 100 lm. Results are presented as the mean AE SD. *P < .05 activation of the PI3K/AKT and HIF-1a pathways has been reported to promote VEGF production and tumor angiogenesis. 24, 25 To examine whether the two pathways are involved in EBV-induced angiogenesis, the PI3K inhibitor LY294002 and the HIF-1a inhibitor PX478 were used. Pretreatment with LY294002 or PX478 reduced EBV-promoted HUVEC migration ( Figure 5B ) and VEGF expression ( Figure 5C,D) . As EBV-induced tumor angiogenesis is mediated by CCL5, we then explored whether CCL5 promotes angiogenesis through the PI3K/AKT and HIF-1a pathways in EBV-infected cells.
We found that inhibiting CCL5/CCR5 signaling with the CCR5 antagonist (DAPTA) decreased AKT phosphorylation and HIF-1a expression ( Figure 5E ). Interestingly, CCL5 expression was also inversely regulated by the PI3K/AKT and HIF-1a pathways, and the two pathways showed a synergistic effect on the regulation of CCL5
( Figure 5F ). In addition, the inhibition of CCL5/CCR5 signaling decreased VEGF expression ( Figure 5G,H) . Taken together, these results suggest that CCL5-promoted tumor angiogenesis is mediated by the PI3K/AKT and HIF-1a pathways.
| Chemokine CCL5 is correlated with angiogenesis in human NPC
To determine the clinical relevance of CCL5 in NPC angiogenesis, we analyzed samples from NPC patients by immunohistochemical 
| DISCUSSION
On the basis of our study, we proposed a novel model of EBVinduced angiogenesis in NPC. In this model, EBV infection promotes the production of CCL5, which increases VEGF expression and NPC angiogenesis by interacting with the PI3K/AKT and HIF-1a pathways ( Figure 6D ).
Among our angiogenesis-related experiments, the HUVEC migration assay in vitro eliminates any additional influences in vivo on factors. 26 Moreover, it has been reported that EBV-infected NPC cells recruit and activate macrophages by inducing granulocyte/ macrophage colony-stimulating factor production. 27 Therefore, our present data could not exclude the indirect effect of EBV infection on tumor angiogenesis.
To understand the molecular basis of EBV-induced angiogenesis,
we compared the proteomics between EBV-infected and EBVuninfected cell lines and found that some angiogenesis-related proteins (ECM1, VEGF, ANG, SRPX2, NOV, ADM, FGFBP1, MMP1, and CCL5) were collectively unregulated in both of the EBV-infected cell lines (CNE2-EBV and TW03-EBV). Among these proteins, only VEGF has been reported to mediate EBV-induced angiogenesis. 6, 7 In this study, we found that CCL5 is another mediator of EBV-induced angiogenesis. By inhibiting CCL5 activity in vitro with receptor antagonists or shRNA knockdown, we revealed that CCL5 is involved in EBV-promoted HUVEC migration. Through investigating microvessel formation in xenograft tumors with CCL5 knockdown, we proved that CCL5 modulates vascular formation of EBV-infected tumors. Thus, our study confirmed that CCL5 mediates EBV-induced angiogenesis. The interaction between CCL5 and the two signaling pathways, PI3K/AKT and HIF-1a, is another notable finding in our study. Tang ) or 50 lmol/L PX478 (HIF-1a inhibitor) for 6 h, and the conditioned media were collected as described previously. The migration of HUVECs was examined by Transwell assays. C,D, Cells were pretreated with LY294002 or PX478 for 6 h and then were cultured in serum-free media. Vascular endothelial growth factor (VEGF) expression was examined by Western blotting and ELISA after 24 h. E, EBV-infected cells were treated with DAPTA for 6 h. Expression of p-AKT and HIF-1a was examined by Western blotting. F, Quantitative real-time PCR analysis of CCL5 expression after cells were treated with LY294002 (10 lmol/L), PX478 (5 lmol/L), or the combination, for 24 h. G,H, Cells were pretreated with DAPTA for 6 h and then were cultured in serum-free media. VEGF expression was examined by Western blotting and ELISA after 24 h. Results are presented as the mean AE SD. *P < .05 vs control; **P < .05 vs LY294002-or PX478-treated group and coworkers have reported that the CCL5/CCR5 axis can modulate these two pathways in human chondrosarcoma and osteosarcoma cells. 18, 32 In EBV-infected NPC cells, we reached a similar conclusion. In addition, we found that these two pathways conversely regulate CCL5 expression. This positive feedback regulation can not only maintain CCL5 production but also continuously activate the PI3K/AKT and HIF-1a pathways. CCL5 both directly acts on tumor cells for angiogenesis and recruits macrophages 33 and regulatory T cells 34 to favor tumor progression. The PI3K/AKT and HIF1a pathways are critical for tumor angiogenesis, survival, growth, and metastasis. 35, 36 Interrupting the feedback regulation could greatly inhibit tumor development, which brings the possibility for CCL5-targeted therapy in NPC. As shown in our data, CCL5 knockdown inhibited EBV-positive tumor angiogenesis and growth. In colorectal cancer patients, a therapy targeting CCL5/CCR5 signaling has shown antitumoral effects. 37 Our findings suggest that CCL5 could also be a potential therapeutic target in NPC and is worthy of further exploration. 
